PMID- 27276528
OWN - NLM
STAT- MEDLINE
DCOM- 20180102
LR  - 20181202
IS  - 2191-0200 (Electronic)
IS  - 0334-1763 (Linking)
VI  - 27
IP  - 7
DP  - 2016 Oct 1
TI  - Incretin-based therapy for type 2 diabetes mellitus is promising for treating 
      neurodegenerative diseases.
PG  - 689-711
LID - 10.1515/revneuro-2016-0018 [doi]
AB  - Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent 
      insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic 
      secretion and improving insulin resistance (IR), incretin-based therapies have 
      become a new class of antidiabetic agents for the treatment of type 2 diabetes 
      mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM 
      have been identified in a number of studies, which suggested that shared 
      mechanisms, such as insulin dysregulation or IR, may underlie these conditions. 
      Therefore, the effects of incretins in neurodegenerative diseases have been 
      extensively investigated. Protease-resistant long-lasting GLP-1 mimetics such as 
      lixisenatide, liraglutide, and exenatide not only have demonstrated promising 
      effects for treating neurodegenerative diseases in preclinical studies but also 
      have shown first positive results in Alzheimer's disease (AD) and Parkinson's 
      disease (PD) patients in clinical trials. Furthermore, the effects of other 
      related incretin-based therapies such as GIP agonists, dipeptidyl peptidase-IV 
      (DPP-IV) inhibitors, oxyntomodulin (OXM), dual GLP-1/GIP, and triple 
      GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been 
      tested in preclinical studies. Incretin-based therapies are a promising approach 
      for treating neurodegenerative diseases.
FAU - Li, Yanwei
AU  - Li Y
FAU - Li, Lin
AU  - Li L
FAU - Holscher, Christian
AU  - Holscher C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Rev Neurosci
JT  - Reviews in the neurosciences
JID - 8711016
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Exenatide
MH  - Gastric Inhibitory Polypeptide/pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incretins/*therapeutic use
MH  - Neurodegenerative Diseases/*drug therapy
MH  - Peptides/therapeutic use
MH  - Venoms/therapeutic use
EDAT- 2016/06/09 06:00
MHDA- 2018/01/03 06:00
CRDT- 2016/06/09 06:00
PHST- 2016/04/11 00:00 [received]
PHST- 2016/05/02 00:00 [accepted]
PHST- 2016/06/09 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
PHST- 2016/06/09 06:00 [entrez]
AID - /j/revneuro.ahead-of-print/revneuro-2016-0018/revneuro-2016-0018.xml [pii]
AID - 10.1515/revneuro-2016-0018 [doi]
PST - ppublish
SO  - Rev Neurosci. 2016 Oct 1;27(7):689-711. doi: 10.1515/revneuro-2016-0018.